Chloromycetin

Trachoma, Dacryocystitis, Bacterial diarrhoea + 15 more
Treatment
4 FDA approvals
11 Active Studies for Chloromycetin

What is Chloromycetin

ChloramphenicolThe Generic name of this drug
Treatment SummaryChloramphenicol is an antibiotic used to treat a wide range of bacterial infections. It was first isolated from a soil-dwelling bacterium in 1947 and can now be made synthetically. Chloramphenicol works by stopping the bacteria from making proteins which allows it to stop the infection. It is usually used as a last resort when other antibiotics have failed.
Chloromycetin Oticis the brand name
Chloromycetin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Chloromycetin Otic
Chloramphenicol
1953
6

Approved as Treatment by the FDA

Chloramphenicol, otherwise known as Chloromycetin Otic, is approved by the FDA for 4 uses including Acne and Bacterial Infections .
Acne
Used to treat Acne in combination with Allantoin
Bacterial Infections
Acne Vulgaris
Used to treat Acne in combination with Allantoin
Urinary Tract Infection (UTI)

Effectiveness

How Chloromycetin Affects PatientsChloramphenicol is a type of antibiotic that can be produced naturally or synthetically. It is very effective in fighting a wide range of infections, but can have serious side effects, so it is usually only used to treat serious illnesses such as typhoid fever. Chloramphenicol works by stopping bacteria from growing and multiplying by binding to the bacteria's ribosome and blocking protein production.
How Chloromycetin works in the bodyChloramphenicol is able to penetrate the outer wall of bacterial cells. Once inside, it binds to a protein in the ribosome, which is responsible for making proteins. This binding stops the ribosome from making proteins, which stops the bacteria from reproducing.

When to interrupt dosage

The proposed measure of Chloromycetin is contingent upon the identified condition, including Keratitis, Bacterial diarrhoea and Communicable Diseases. The degree of dosage also depends on the method of administration as specified in the table below.
Condition
Dosage
Administration
Conjunctivitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Postoperative
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Allergic Conjunctivitis (AC)
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Bacterial conjunctivitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Trachoma
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Dacryocystitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Acne Vulgaris
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Blepharitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Urinary Tract Infection (UTI)
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Conjunctivitis, Bacterial
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Conjunctivitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
bacterial corneal ulcers
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
swelling of the eyes
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Conjunctivitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Communicable Diseases
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Disinfection
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Keratitis
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous
Bacterial diarrhoea
, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Ophthalmic, Solution - Ophthalmic, Ointment, Ointment - Ophthalmic, Auricular (otic); Ophthalmic, Suspension, Suspension - Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid - Ophthalmic, Liquid, Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic; Topical, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, for solution - Topical, Topical, Powder, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Warnings

Chloromycetin Contraindications
Condition
Risk Level
Notes
prophylaxis of infection in minor cuts, scrapes, or burns
Do Not Combine
Communicable Diseases
Do Not Combine
There are 20 known major drug interactions with Chloromycetin.
Common Chloromycetin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abatacept.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Chloramphenicol.
Abetimus
Major
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abetimus.
Chloromycetin Toxicity & Overdose RiskThe lowest toxic dose of this drug in mice is 1500 mg/kg, and in rats it is 2500 mg/kg. Premature infants and newborns are especially vulnerable to overdosing on this drug, and the resulting symptoms are known as the "gray syndrome". These include swelling of the abdomen, vomiting, pale blue skin, weak blood circulation, and irregular breathing, which can lead to death within a few hours.
image of a doctor in a lab doing drug, clinical research

Chloromycetin Novel Uses: Which Conditions Have a Clinical Trial Featuring Chloromycetin?

41 active clinical trials are currently being conducted to assess the potential of Chloromycetin to mitigate anterior eye segment inflammation, Inflammation Corneal and superficial ocular infections.
Condition
Clinical Trials
Trial Phases
Allergic Conjunctivitis (AC)
1 Actively Recruiting
Phase 2
Conjunctivitis
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Blepharitis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
swelling of the eyes
0 Actively Recruiting
Bacterial diarrhoea
0 Actively Recruiting
Bacterial conjunctivitis
0 Actively Recruiting
Dacryocystitis
0 Actively Recruiting
Trachoma
1 Actively Recruiting
Phase 4
Conjunctivitis
0 Actively Recruiting
bacterial corneal ulcers
0 Actively Recruiting
Conjunctivitis, Bacterial
0 Actively Recruiting
Postoperative
3 Actively Recruiting
Not Applicable, Early Phase 1
Keratitis
0 Actively Recruiting
Conjunctivitis
0 Actively Recruiting
Disinfection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting

Chloromycetin Reviews: What are patients saying about Chloromycetin?

4.3Patient Review
11/23/2014
Chloromycetin for Pink Eye from Bacterial Infection
Chloromycetin was very effective in treating my pink eye. The itching stopped after a few days and it cleared up completely within a week!
4Patient Review
1/25/2013
Chloromycetin for Pink Eye from Bacterial Infection
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about chloromycetin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of antibiotic is chloromycetin?

"The study of microorganisms. Chloramphenicol is an antibiotic that was originally found in Streptomyces venezuelae. It prevents bacterial protein synthesis by disruptiing the transfer of activated amino acids from RNA to ribosomes."

Answered by AI

What are the side effects of chloromycetin?

"The medicine may cause some serious side effects, including blood problems and eye problems. Symptoms of the blood problems include pale skin, sore throat and fever, unusual bleeding or bruising, and unusual tiredness or weakness."

Answered by AI

What is chloromycetin used for?

"It will not work for other types of eye infections.

This eye drop is for treating bacterial eye infections only. Chloramphenicol stops the growth of bacteria. Do not use this drop for any other eye infections."

Answered by AI

Clinical Trials for Chloromycetin

Image of University of Virginia in Charlottesville, United States.

Methadone vs Remifentanil for Pain in Craniotomy Surgery

18 - 65
All Sexes
Charlottesville, VA
Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.
Phase < 1
Waitlist Available
University of Virginia
Have you considered Chloromycetin clinical trials? We made a collection of clinical trials featuring Chloromycetin, we think they might fit your search criteria.Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
Phase 4
Recruiting
University of MissouriKevin M Klifto, DO, PharmD
Image of Toronto Western Hospital?UHN in Toronto, Canada.

ESP Block for Post-Surgery Pain

18 - 80
All Sexes
Toronto, Canada
Patients undergoing spine surgery frequently experience significant pain after surgery. This can limit patient activity and hinder rehabilitation. If inadequately treated, severe pain can result in emotional and psychological distress and ultimately impact long-term function, and increase the risk of developing pain that lasts longer than six months associated with depression, anxiety and disability. More specifically, Erector Spinae Plane (ESP) block is a recently described plane block designed to block the dorsal and ventral rami of the thoracic spinal nerves. It has shown to be an effective modality for postoperative pain management as a part of multimodal analgesia in spinal surgery.
Recruiting
FDA Approved Drug
Toronto Western Hospital?UHNMichael Dinsmore, MD
Have you considered Chloromycetin clinical trials? We made a collection of clinical trials featuring Chloromycetin, we think they might fit your search criteria.Go to Trials